Summary
Total and free plasma concentrations of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-E) were determined in 39 children (aged 3 to 10 years) and 79 adults (aged 15 to 65 years) receiving long term treatment with CBZ alone or in combination with phenobarbitone (PB).
Compared with the corresponding age groups treated with CBZ alone, adults and children receiving PB co-medication showed lower total and free CBZ concentrations, similar CBZ-E concentrations and higher CBZ-E/CBZ ratios. Among patients on CBZ alone, children had at any given dose lower total and free CBZ and CBZ-E concentrations than adults. Lower CBZ levels in children than in adults were also found among patients receiving phenobarbitone in combination. CBZ-E/CBZ ratios did not differ significantly between children and adults. These data provide evidence that children show an elevated free CBZ clearance with a metabolic pattern different from that observed during phenobarbitone induction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Batlino, D.: Bossi, L.: Croci, D.: Franceschetti, S.: Gomeni, C. et al.: Carbamazepine plasma levels in children and adults: Influence of age, dose and associated therapy. Therapeutic Drug Monitoring 2: 315–327 (1980).
Bertilsson, L: Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics 3: 128–143 (1978).
Bourgeois, B.F.D. and Wad, N.: Carbamazepine 10, 11 diol steadystate serum levels and renal excretion during carbamazepine thcrapy in adults and children. Therapeutic Drug Monitoring 6: 259–265 (1984).
Christiansen, J. and Dam, M.: Drug interaction in epileptic patients: in Schneider et al. (Eds) Clinical Pharmacology of Antiepileptic Drugs, pp. 197–200 (Springer Verlag, Berlin, Heidelberg, New York 1975).
Contin, M.: Riva, R.: Albani, F.: Perucca, E. and Baruzzi, A.: Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: Interference with the 10,11-epoxide metabolite. Therapeutic Drug Monitoring 7: 46–50 (1985).
Dam, M.: Jensen, A. and Christiansen, J.: Plasma level and effect of CBZ in grand mal and psychomotor epilepsy. Acta Neurologica Scandinavica 56: 603–607 (1975).
Eichelbaum, M.: Kothe, K.W.: Hoffmann, F. and VonUnruh, G.E.: Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clinical Pharmacology and Therapeutics 26: 366–371 (1979).
Frigerio, A. and Morselli, P.L.: Carbamazepine: Biotransformation; in Penry and Daly (Eds) Complex Partial Seizures and Their Treatment. Advances in Neurology, Vol. 11, pp. 295–308 (Raven Press, New York 1975).
Hoppener, R.J.: Kuyer, A.: Meijer, J.W.A. and Hulsman, J.: Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 21: 341–350 (1980).
Kumps, A.H.: Dose-dependency of the ratio between carbamazepine serum level and dosage in patients with epilepsy. Therapeutic Drug Monitoring 3: 271–274 (1981).
Lawless, L.M.: DeMonaco, H.J. and Muido, L.R.: Protein binding of carbamazepine in epileptic patients. Neurology 32: 415–418 (1982).
Levy, R.H.: Friel, P.N.: Johno, I.: Linthicum, L.M.: Colin, L. et al.: Filtration for free drug level monitoring: Carbamazepine and valproic acid. Therapeutic Drug Monitoring 6: 67–76 (1984).
McKauge, L.: Tyrer, J.H. and Eadie, M.J.: Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Therapeutic Drug Monitoring 3: 63–70 (1981)
MacKichan, J.J.: Duffner, P.K. and Cohen, M.E.: Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. British Journal of Clinical Pharmacology 12: 31–37 (1981).
Meijer, J.W.A.: Binnie, C.D.: Debets, R.M.: Van Paris, J.A.P. and DeBeer-Pawlikowski, N.K.B.: Possible hazard of valpromidecarbamazepine combination therapy in epilepsy. Lancet 1: 802 (1984).
Morselli, P.L.: Antiepileptic drugs; in Morselli (Ed.) Drug Disposition During Development, pp. 311–360 (Spectrum Publishers, New York 1977).
Parsonage, M.: Treatment with carbamazepine: Adults; in Penry and Daly (Eds) Complex Partial Seizures and Their Treatment. Advances in Neurology, Vol. 11, pp. 221–236 (Raven Press, New York 1975).
Patel, I.H.: Wedlund, P.L. and Levy, R.H.: Induction effect of phenobarbital on the carbamazepine to carbamazepine-10,11-epoxide pathway in rhesus monkey. Journal of Pharmacology and Experimental Therapeutics 217: 555–558 (1981).
Perucca, E.: Pharmacokinetic interactions with antiepileptic drugs. Clinical Pharmacokinetics 7: 57–84 (1982).
Perucca, E.: Biltencourt, P. and Richens, A.: Effect of dose increments on serum carbamazepine concentration in epileptic patients. Clinical Pharmacokinetics 6: 576–582 (1980).
Pynnonen, S.: Pharmacokinctics of carbamazepine in man: A review. Therapeutic Drug Monitoring 1: 409–431 (1979).
Pynnönen, S.: Sillanpaa, M.: Frey, H. and Iisolo, E.: Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. European Journal of Clinical Pharmacology 11: 129–133 (1977).
Rane, A.: Hojer, B. and Wilson, J.T.: Kinetics of carbamazepine and its 10,11 epoxide metabolite in children. Clinical Pharmacology and Therapeutics 19: 276–283 (1976).
Riva, R.: Albani, F.: Ambrosetto, G.: Contin, M.: Cortellsi, P. et al.: Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 25: 476–481 (1984a).
Riva, R.: Contin, M.: Albani, F.: Perucca, E.: Ambrosetto, G. et al.: Free and total plasma concentrations of carbamazepine and carbamazepine 10,11 epoxide in epileptic patients: Diurnal fluctuations and relationship with side effects. Therapeutic Drug Monitoring 6: 408–413 (1984b).
Riva, R.: Contin, M.: Albani, F.: Perucca, E.: Ambrosetto, G. et al.: Lateral gaze nystagmus and carbamazepine: Incidence and correlation with free and total plasma drug concentrations in a large population of patients with epilepsy. Therapeutic Drug Monitoring (In press 1985).
Schain, R.J.: Ward, J.W. and Guthrie, D.: Carbamazepine as an anticonvulsant in children. Neurology 27: 476–480 (1977).
Schneider, H.: Carbamazepine: The influence of other antiepileptic drugs on its serum levels; in Scheider et al. (Eds) Clinical Pharmacology of Antiepileptic Drugs, pp. 189–196 (Springer Verlag, Berlin, Heidelberg, New York 1975).
Tomson, T.: Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Archives of Neurology 41: 830–834 (1984).
Tomson, T. and Bertilsson, L.: Potential therapeutic effect of carbamazepine-10.11-epoxide in trigeminal neuralgia. Archives of Neurology 41: 598–601 (1984).
Tybring, G.: VonBahr, C.: Bertilsson, L.: Collste, H.: Glauman, H. and Solbrand, M.: Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metabolism and Disposition 9: 561–564 (1981).
Wedlund, P.L.: Patel, I.H. and Levy, R.H.: Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. Journal of Pharmacokinetics and Biopharmaceutics 10: 427–435 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Riva, R., Contin, M., Albani, F. et al. Free Concentration of Carbamazepine and Carbamazepine-10,11-Epoxide in Children and Adults. Clin Pharmacokinet 10, 524–531 (1985). https://doi.org/10.2165/00003088-198510060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198510060-00005